Esophageal adenocarcinoma arising in Barrett esophagus

Cancer Letters

Volumn 275, Issue 2, 2009, Pages 170-177

  Zhang, Hui Ying ^a   Spechler, Stuart Jon ^a,b   Souza, Rhonda F ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Barrett esophagus; Esophageal adenocarcinoma; Metaplasia; Stem cells

Indexed keywords

ANGIOGENESIS; APOPTOSIS; BARRETT ESOPHAGUS; CANCER INVASION; CANCER RISK; CARCINOGENESIS; CELL DIFFERENTIATION; ESOPHAGEAL ADENOCARCINOMA; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; SHORT SURVEY; SQUAMOUS CELL METAPLASIA; STEM CELL;

EID: 59549100166     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2008.07.006     Document Type: Review

References (71)

1. Lambert R., and Hainaut P. The multidisciplinary management of gastrointestinal cancer. Epidemiology of oesophagogastric cancer. Best Pract. Res. Clin. Gastroenterol. 21 (2007) 921-945
2. Holmes R.S., and Vaughan T.L. Epidemiology and pathogenesis of esophageal cancer. Semin. Radiat. Oncol. 17 (2007) 2-9
3. Pohl H., and Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J. Natl. Cancer Inst. 97 (2005) 142-146
4. Lagergren J., Bergstrom R., Lindgren A., and Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N. Engl. J. Med. 340 (1999) 825-831
5. Spechler S.J. Clinical practice. Barrett's esophagus. N. Engl. J. Med. 346 (2002) 836-842
6. Souza R.F., Morales C.P., and Spechler S.J. Review article: a conceptual approach to understanding the molecular mechanisms of cancer development in Barrett's oesophagus. Aliment. Pharmacol. Ther. 15 (2001) 1087-1100
7. Kubo A., and Corley D.A. Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol. Biomarkers Prev. 15 (2006) 872-878
8. Corley D.A., Kubo A., and Zhao W. Abdominal obesity and the risk of esophageal and gastric cardia carcinomas. Cancer Epidemiol. Biomarkers Prev. 17 (2008) 352-358
9. El Serag H.B., Kvapil P., Hacken-Bitar J., and Kramer J.R. Abdominal obesity and the risk of Barrett's esophagus. Am. J. Gastroenterol. 100 (2005) 2151-2156
10. Frystyk J., Skjaerbaek C., Vestbo E., Fisker S., and Orskov H. Circulating levels of free insulin-like growth factors in obese subjects: the impact of type 2 diabetes. Diabetes Metab. Res. Rev. 15 (1999) 314-322
11. Iijima K., Henry E., Moriya A., Wirz A., Kelman A.W., and McColl K.E. Dietary nitrate generates potentially mutagenic concentrations of nitric oxide at the gastroesophageal junction. Gastroenterology 122 (2002) 1248-1257
12. Spechler S.J. Carcinogenesis at the gastroesophageal junction: free radicals at the frontier. Gastroenterology 122 (2002) 1518-1520
13. Freedman N.D., Park Y., Subar A.F., Hollenbeck A.R., Leitzmann M.F., Schatzkin A., and Abnet C.C. Fruit and vegetable intake and esophageal cancer in a large prospective cohort study. Int. J. Cancer 121 (2007) 2753-2760
14. Crew K.D., and Neugut A.I. Epidemiology of upper gastrointestinal malignancies. Semin. Oncol. 31 (2004) 450-464
15. Rokkas T., Pistiolas D., Sechopoulos P., Robotis I., and Margantinis G. Relationship between Helicobacter pylori infection and esophageal neoplasia: a meta-analysis. Clin. Gastroenterol. Hepatol. 5 (2007) 1413-1417 1417. e1-2
16. Corley D.A., Kubo A., Levin T.R., Block G., Habel L., Zhao W., Leighton P., Rumore G., Quesenberry C., Buffler P., and Parsonnet J. Helicobacter pylori infection and the risk of Barrett's oesophagus: a community-based study. Gut 57 (2008) 727-733
17. Freedman N.D., Abnet C.C., Leitzmann M.F., Mouw T., Subar A.F., Hollenbeck A.R., and Schatzkin A. A prospective study of tobacco, alcohol, and the risk of esophageal and gastric cancer subtypes. Am. J. Epidemiol. 165 (2007) 1424-1433
18. Tosh D., and Slack J.M. How cells change their phenotype. Nat. Rev. Mol. Cell Biol. 3 (2002) 187-194
19. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 (2000) 57-70
20. Arber N., Lightdale C., Rotterdam H., Han K.H., Sgambato A., Yap E., Ahsan H., Finegold J., Stevens P.D., Green P.H., Hibshoosh H., Neugut A.I., Holt P.R., and Weinstein I.B. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol. Biomarkers Prev. 5 (1996) 457-459
21. Sarbia M., Bektas N., Muller W., Heep H., Borchard F., and Gabbert H.E. Expression of cyclin E in dysplasia, carcinoma, and nonmalignant lesions of Barrett esophagus. Cancer 86 (1999) 2597-2601
22. Geddert H., Heep H.J., Gabbert H.E., and Sarbia M. Expression of cyclin B1 in the metaplasia-dysplasia-carcinoma sequence of Barrett esophagus. Cancer 94 (2002) 212-218
23. Lao-Sirieix P., Lovat L., and Fitzgerald R.C. Cyclin A immunocytology as a risk stratification tool for Barrett's esophagus surveillance. Clin. Cancer Res. 13 (2007) 659-665
24. Jankowski J., Hopwood D., and Wormsley K.G. Flow-cytometric analysis of growth-regulatory peptides and their receptors in Barrett's oesophagus and oesophageal adenocarcinoma. Scand. J. Gastroenterol. 27 (1992) 147-154
25. Brito M.J., Filipe M.I., Linehan J., and Jankowski J. Association of transforming growth factor alpha (TGFA) and its precursors with malignant change in Barrett's epithelium: biological and clinical variables. Int. J. Cancer 60 (1995) 27-32
26. Brien T.P., Odze R.D., Sheehan C.E., McKenna B.J., and Ross J.S. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum. Pathol. 31 (2000) 35-39
27. Reichelt U., Duesedau P., Tsourlakis M.C., Quaas A., Link B.C., Schurr P.G., Kaifi J.T., Gros S.J., Yekebas E.F., Marx A., Simon R., Izbicki J.R., and Sauter G. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Mod. Pathol. 20 (2007) 120-129
28. Lord R.V., O'Grady R., Sheehan C., Field A.F., and Ward R.L. K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction. J. Gastroenterol. Hepatol. 15 (2000) 730-736
29. Sommerer F., Vieth M., Markwarth A., Rohrich K., Vomschloss S., May A., Ell C., Stolte M., Hengge U.R., Wittekind C., and Tannapfel A. Mutations of BRAF and KRAS2 in the development of Barrett's adenocarcinoma. Oncogene 23 (2004) 554-558
30. Barrett M.T., Sanchez C.A., Galipeau P.C., Neshat K., Emond M., and Reid B.J. Allelic loss of 9p21 and mutation of the CDKN2/p16 gene develop as early lesions during neoplastic progression in Barrett's esophagus. Oncogene 13 (1996) 1867-1873
31. Wong D.J., Barrett M.T., Stoger R., Emond M.J., and Reid B.J. p16INK4a promoter is hypermethylated at a high frequency in esophageal adenocarcinomas. Cancer Res. 57 (1997) 2619-2622
32. Wong D.J., Paulson T.G., Prevo L.J., Galipeau P.C., Longton G., Blount P.L., and Reid B.J. p16(INK4a) lesions are common, early abnormalities that undergo clonal expansion in Barrett's metaplastic epithelium. Cancer Res. 61 (2001) 8284-8289
33. Hamelin R., Flejou J.F., Muzeau F., Potet F., Laurent-Puig P., Fekete F., and Thomas G. TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. Gastroenterology 107 (1994) 1012-1018
34. Galipeau P.C., Prevo L.J., Sanchez C.A., Longton G.M., and Reid B.J. Clonal expansion and loss of heterozygosity at chromosomes 9p and 17p in premalignant esophageal (Barrett's) tissue. J. Natl. Cancer Inst. 91 (1999) 2087-2095
35. Maley C.C., Galipeau P.C., Li X., Sanchez C.A., Paulson T.G., Blount P.L., and Reid B.J. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma. Cancer Res. 64 (2004) 7629-7633
36. Y. Huang, C.J. Peters, R.C. Fitzgerald, R.A. Gjerset, Progressive silencing of p14ARF in oesophageal adenocarcinoma, J. Cell Mol. Med. (in press).
37. Singh S.P., Lipman J., Goldman H., Ellis Jr. F.H., Aizenman L., Cangi M.G., Signoretti S., Chiaur D.S., Pagano M., and Loda M. Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. Cancer Res. 58 (1998) 1730-1735
38. Kawakami K., Brabender J., Lord R.V., Groshen S., Greenwald B.D., Krasna M.J., Yin J., Fleisher A.S., Abraham J.M., Beer D.G., Sidransky D., Huss H.T., DeMeester T.R., Eads C., Laird P.W., Ilson D.H., Kelsen D.P., Harpole D., Moore M.B., Danenberg K.D., Danenberg P.V., and Meltzer S.J. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J. Natl. Cancer Inst. 92 (2000) 1805-1811
39. Clement G., Jablons D.M., and Benhattar J. Targeting the Wnt signaling pathway to treat Barrett's esophagus. Expert Opin. Ther. Targets 11 (2007) 375-389
40. Hetts S.W. To die or not to die: an overview of apoptosis and its role in disease. JAMA 279 (1998) 300-307
41. Suda T., Takahashi T., Golstein P., and Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 75 (1993) 1169-1178
42. Popnikolov N.K., Gatalica Z., Adegboyega P.A., Norris B.A., and Pasricha P.J. Downregulation of TNF-related apoptosis-inducing ligand (TRAIL)/Apo2L in Barrett's esophagus with dysplasia and adenocarcinoma. Appl. Immunohistochem. Mol. Morphol. 14 (2006) 161-165
43. Younes M., Schwartz M.R., Ertan A., Finnie D., and Younes A. Fas ligand expression in esophageal carcinomas and their lymph node metastases. Cancer 88 (2000) 524-528
44. Souza R.F., Shewmake K., Beer D.G., Cryer B., and Spechler S.J. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res. 60 (2000) 5767-5772
45. Wilson K.T., Fu S., Ramanujam K.S., and Meltzer S.J. Increased expression of inducible nitric oxide synthase and cyclooxygenase-2 in Barrett's esophagus and associated adenocarcinomas. Cancer Res. 58 (1998) 2929-2934
46. Shirvani V.N., Ouatu-Lascar R., Kaur B.S., Omary M.B., and Triadafilopoulos G. Cyclooxygenase 2 expression in Barrett's esophagus and adenocarcinoma: ex vivo induction by bile salts and acid exposure. Gastroenterology 118 (2000) 487-496
47. Shay J.W., and Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer 33 (1997) 787-791
48. Morales C.P., Lee E.L., and Shay J.W. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma. Cancer 83 (1998) 652-659
49. Saad R.S., El Gohary Y., Memari E., Liu Y.L., and Silverman J.F. Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in esophageal adenocarcinoma. Hum. Pathol. 36 (2005) 955-961
50. Bailey T., Biddlestone L., Shepherd N., Barr H., Warner P., and Jankowski J. Altered cadherin and catenin complexes in the Barrett's esophagus-dysplasia-adenocarcinoma sequence: correlation with disease progression and dedifferentiation. Am. J. Pathol. 152 (1998) 135-144
51. Washington K., Chiappori A., Hamilton K., Shyr Y., Blanke C., Johnson D., Sawyers J., and Beauchamp D. Expression of beta-catenin, alpha-catenin, and E-cadherin in Barrett's esophagus and esophageal adenocarcinomas. Mod. Pathol. 11 (1998) 805-813
52. Salmela M.T., Karjalainen-Lindsberg M.L., Puolakkainen P., and Saarialho-Kere U. Upregulation and differential expression of matrilysin (MMP-7) and metalloelastase (MMP-12) and their inhibitors TIMP-1 and TIMP-3 in Barrett's oesophageal adenocarcinoma. Br. J. Cancer 85 (2001) 383-392
53. Herszenyi L., Hritz I., Pregun I., Sipos F., Juhasz M., Molnar B., and Tulassay Z. Alterations of glutathione-S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis. World J. Gastroenterol. 13 (2007) 676-682
54. O'Riordan J.M., Abdel-latif M.M., Ravi N., McNamara D., Byrne P.J., McDonald G.S., Keeling P.W., Kelleher D., and Reynolds J.V. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am. J. Gastroenterol. 100 (2005) 1257-1264
55. Fitzgerald R.C., Abdalla S., Onwuegbusi B.A., Sirieix P., Saeed I.T., Burnham W.R., and Farthing M.J. Inflammatory gradient in Barrett's oesophagus: implications for disease complications. Gut 51 (2002) 316-322
56. Fitzgerald R.C., Onwuegbusi B.A., Bajaj-Elliott M., Saeed I.T., Burnham W.R., and Farthing M.J. Diversity in the oesophageal phenotypic response to gastro-oesophageal reflux: immunological determinants. Gut 50 (2002) 451-459
57. Tselepis C., Perry I., Dawson C., Hardy R., Darnton S.J., McConkey C., Stuart R.C., Wright N., Harrison R., and Jankowski J.A. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene 21 (2002) 6071-6081
58. Chen X., Ding Y.W., Yang G., Bondoc F., Lee M.J., and Yang C.S. Oxidative damage in an esophageal adenocarcinoma model with rats. Carcinogenesis 21 (2000) 257-263
59. Wetscher G.J., Hinder R.A., Bagchi D., Hinder P.R., Bagchi M., Perdikis G., and McGinn T. Reflux esophagitis in humans is mediated by oxygen-derived free radicals. Am. J. Surg. 170 (1995) 552-556
60. Clemons N.J., McColl K.E., and Fitzgerald R.C. Nitric oxide and acid induce double-strand DNA breaks in Barrett's esophagus carcinogenesis via distinct mechanisms. Gastroenterology 133 (2007) 1198-1209
61. Cobbe S.C., Scobie G.C., Pohler E., Hayes J.D., Kernohan N.M., and Dillon J.F. Alteration of glutathione-S-transferase levels in Barrett's metaplasia compared to normal oesophageal epithelium. Eur. J. Gastroenterol. Hepatol. 15 (2003) 41-47
62. Lee O.J., Schneider-Stock R., McChesney P.A., Kuester D., Roessner A., Vieth M., Moskaluk C.A., and El Rifai W. Hypermethylation and loss of expression of glutathione peroxidase-3 in Barrett's tumorigenesis. Neoplasia 7 (2005) 854-861
63. Sarosi G., Brown G., Jaiswal K., Feagins L.A., Lee E., Crook T.W., Souza R.F., Zou Y.S., Shay J.W., and Spechler S.J. Bone marrow progenitor cells contribute to esophageal regeneration and metaplasia in a rat model of Barrett's esophagus. Dis. Esophagus 21 (2008) 43-50
64. Silberg D.G., Sullivan J., Kang E., Swain G.P., Moffett J., Sund N.J., Sackett S.D., and Kaestner K.H. Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 122 (2002) 689-696
65. Mutoh H., Sakurai S., Satoh K., Osawa H., Hakamata Y., Takeuchi T., and Sugano K. Cdx1 induced intestinal metaplasia in the transgenic mouse stomach: comparative study with Cdx2 transgenic mice. Gut 53 (2004) 1416-1423
66. Wong N.A., Wilding J., Bartlett S., Liu Y., Warren B.F., Piris J., Maynard N., Marshall R., and Bodmer W.F. CDX1 is an important molecular mediator of Barrett's metaplasia. Proc. Natl. Acad. Sci. USA 102 (2005) 7565-7570
67. Moons L.M., Bax D.A., Kuipers E.J., van Dekken H., Haringsma J., Van Vliet A.H., Siersema P.D., and Kusters J.G. The homeodomain protein CDX2 is an early marker of Barrett's oesophagus. J. Clin. Pathol. 57 (2004) 1063-1068
68. Liu T., Zhang X., So C.K., Wang S., Wang P., Yan L., Myers R., Chen Z., Patterson A.P., Yang C.S., and Chen X. Regulation of Cdx2 expression by promoter methylation, and effects of Cdx2 transfection on morphology and gene expression of human esophageal epithelial cells. Carcinogenesis 28 (2007) 488-496
69. Milano F., van Baal J.W., Buttar N.S., Rygiel A.M., de Kort F., DeMars C.J., Rosmolen W.D., Bergman J.J., VAn M.J., Wang K.K., Peppelenbosch M.P., and Krishnadath K.K. Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells. Gastroenterology 132 (2007) 2412-2421
70. Barker N., van Es J.H., Kuipers J., Kujala P., van den B.M., Cozijnsen M., Haegebarth A., Korving J., Begthel H., Peters P.J., and Clevers H. Identification of stem cells in small intestine and colon by marker gene Lgr5. Nature 449 (2007) 1003-1007
71. May R., Riehl T.E., Hunt C., Sureban S.M., Anant S., and Houchen C.W. Identification of a novel putative gastrointestinal stem cell and adenoma stem cell marker, doublecortin and CaM kinase-like-1, following radiation injury and in adenomatous polyposis coli/multiple intestinal neoplasia mice. Stem Cells 26 (2008) 630-637